1. Home
  2. UHT vs DRUG Comparison

UHT vs DRUG Comparison

Compare UHT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UHT

Universal Health Realty Income Trust

HOLD

Current Price

$42.61

Market Cap

596.5M

Sector

Real Estate

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$90.00

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHT
DRUG
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
596.5M
707.1M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
UHT
DRUG
Price
$42.61
$90.00
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$43.00
$129.25
AVG Volume (30 Days)
51.3K
142.5K
Earning Date
04-24-2026
05-14-2026
Dividend Yield
7.00%
N/A
EPS Growth
N/A
N/A
EPS
1.27
N/A
Revenue
$99,190,000.00
N/A
Revenue This Year
$2.12
N/A
Revenue Next Year
$2.94
N/A
P/E Ratio
$33.52
N/A
Revenue Growth
0.18
N/A
52 Week Low
$35.26
$23.18
52 Week High
$44.70
$123.75

Technical Indicators

Market Signals
Indicator
UHT
DRUG
Relative Strength Index (RSI) 53.37 67.59
Support Level $41.96 $69.83
Resistance Level $43.22 $91.00
Average True Range (ATR) 0.78 4.46
MACD 0.14 1.50
Stochastic Oscillator 71.17 92.08

Price Performance

Historical Comparison
UHT
DRUG

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: